Next Article in Journal
New Genetically Determined Markers of the Functional State of the Cardiovascular System
Previous Article in Journal
Genetic Insights from Consanguineous Cardiomyopathy Families
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Genes
Volume 14
Issue 1
10.3390/genes14010184
genes-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Gene Expression in MC3T3-E1 Cells Treated with Diclofenac and Methylprednisolone

by
Tomasz P. Lehmann
1,*,
Ewa Iwańczyk-Skalska
1,
Jerzy Harasymczuk
2,
Paweł P. Jagodziński
1 and
Maciej Głowacki
3
1
Department of Biochemistry and Molecular Biology, Poznań University of Medical Sciences, Święcickiego 6, 60-781 Poznan, Poland
2
Department of Paediatric Surgery, Traumatology and Urology, Poznan University of Medical Sciences, Szpitalna 27/33, 60-572 Poznan, Poland
3
Department of Paediatric Orthopaedics and Traumatology, Poznan University of Medical Sciences, 28 Czerwca 1956 135/147, 61-545 Poznan, Poland
*
Author to whom correspondence should be addressed.
Genes 2023, 14(1), 184; https://doi.org/10.3390/genes14010184
Submission received: 16 December 2022 / Revised: 26 December 2022 / Accepted: 5 January 2023 / Published: 10 January 2023
(This article belongs to the Section Human Genomics and Genetic Diseases)
Browse Figures
Review Reports Versions Notes

Abstract

:
Nonsteroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids (GCs) are often used to treat articular-skeletal disorders. The extended use of NSAIDs and GCs have adverse effects on bone metabolism, reducing bone quality and impairing fracture healing. In the present study, we used mouse pre-osteoblast cells MC3T3-E1 to demonstrate the effects of diclofenac (DF) and methylprednisolone (MP) on cell proliferation and gene expression. Cells were incubated with three doses of DF or MP: 0.5 µM, 5 µM, and 50 µM. MP decreased cell viability even after 24 h, but DF inhibited cell viability after only seven days of treatment. The cells were lysed after one, two, three, and seven days of treatment, and gene expression was analyzed by reverse transcription and quantitative PCR (RT-qPCR) assays. DF did not significantly affect the expression of the osteogenic marker genes. MP modified the expression of Osx, Runx, and Col1a1. We concluded that MP is a more potent inhibitor of mouse pre-osteoblast differentiation and viability than is DF. Our results suggest that prolonged DF treatment could be less harmful to osteoblasts than MP treatment.

Graphical Abstract

1. Introduction

Nonsteroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids (GCs) are frequently used in addition to opioids to control pain. NSAIDs are one of the most used therapeutics which may be obtained over the counter in many countries. NSAIDs are used for a wide variety of indications, including short-term and long-term treatment of pain [1]. Long-term pain accompanies inflammation in patients with chronic musculoskeletal diseases, fractures, and osteoarthritis [2]. Diclofenac (DF) and methylprednisolone (MP) are prescribed after surgery for postoperative pain management. Long-term and even low-dose glucocorticoid treatment can cause decreased osteoblast viability and function, leading to osteoporosis and osteonecrosis [3]. The chronic administration of GCs exhibits a substantial risk factor for fragility and osteopenia in humans and mice. Numerous studies have demonstrated that GCs negatively affect bone metabolism, leading to the deterioration of tissue quantity and quality [4,5]. GCs act directly on the glucocorticoid receptors in osteoblasts and osteocytes, inducing apoptosis, but they are also essential in regulating genes involved in osteoblast differentiation [3].
In the human body, under the influence of drugs, as well as local processes (metabolic disorders, genetic disease), the bone structure may be weakened in some situations, leading to pathological titers [6,7,8].
In combination with GCs in chronic articular-skeletal pain treatment, DF is frequently prescribed. Diclofenac, sodium 2-(2,6-dichloroanilino)-phenylacetate, is a member of the aryl acetic acid group of NSAIDs [9]. The anti-inflammatory efficacy of DF is undeniable; however, the side effect on bone healing has been reported [10]. The chronic administration of NSAIDs, such as DF, negatively affects the skeletal system [11]. Earlier results have suggested that DF mediates cyclooxygenase 2 (COX-2) inhibition in the early phase of bone healing and harms osteoblast, osteoclast, and macrophage activity [12].
Many studies have shown that NSAIDs, including DF, decreased osteoblast proliferation and differentiation [13,14,15]. The typical mechanism of NSAIDs and DF action on cells is the inhibition of cyclooxygenases and subsequently, prostaglandin synthesis [16]. DF and other NSAIDs can interfere with the human and mouse bone marrow mesenchymal stem cell cycle by arresting the G0/G1 phase [17]. In the human MG-63 osteosarcoma cell line, however, treatment with DF, which reduces cell proliferation capacity, produced no cell cycle changes [18]. DF also inhibited osteoclast differentiation, without triggering cell apoptosis [19]. DF induced the accumulation of the inhibitor of kappa B in the cytosol, which led to the suppression of the nuclear translocation of NFκB (nuclear factor κ-light-chain-enhancer of activated B cells). There have been several types of research regarding the impact of DF on mouse MC3T3-E1 cells. These pre-osteoblasts can synthesize prostaglandin; nevertheless, NSAIDs diminish MC3T3-E1 proliferation by cyclooxygenase and prostaglandin-independent mechanisms [9,11].
The adverse effects of NSAIDs and GCs on bone are well known, but the DF mechanism and its impact on gene expression have yet to be well established. Some gene expression studies have already been conducted on MC3T3-E1. Hadjicharalambous states that neither DF nor any of the NSAIDs investigated in their study inhibit Runx2 or Bsp gene expression [14]. In the D1-cell mouse mesenchymal stem cell line, DF showed no significant effect on expressions of the osteogenic markers, Runx2, Bmp2, Col1a1, and Ocn (osteocalcin) [15]. Melguizo-Rodríguez et al. found that in human osteoblast lines, DF and other NSAIDs inhibited the expression of RUNX2, COL1A1, OSX, and BGLAP (osteocalcin) [20]. The sensitivity of gene expression to the presence of DF and NSAIDs depends on the cell type.
A short review of the literature concerning NSAIDs’ effect on bone has revealed the ambiguity of the presented data in human, animal, and in vitro studies [21]. The mechanisms which cause this ambiguity need to be better understood. To date, there is no consensus regarding the impact of DF on bone healing and the effects of DF on cultured cells. Therefore, we looked for a cellular model which is closely related to animal species. Previously using the C57BL/6J mouse strain, we demonstrated that DF decreased murine bone mineral density [22]. To explain this decrease in bone mineral density, we hypothesized osteoblast dysfunction caused by DF. As the experimental model, we used MC3T3-E1 pre-osteoblast cells derived from the C57BL/6J mouse strain.
In the present study, we used the mouse osteoblast progenitor cells MC3T3-E1 to demonstrate DF and MP treatment on cell proliferation and gene expression. Osteoblasts participate in bone formation and remodeling, promoting the regeneration of damaged bone tissue [12]. Therefore, using MC3T3-E1 cells, we addressed the objective of this study. The study will improve our understanding of the role of osteoblasts in DF mechanisms on bone turnover. This in vitro experimental study may contribute to elucidating the mechanism underlying the action of NSAIDs on osteoblasts and, therefore, on bone.

2. Materials and Methods

2.1. Cell Culture

The MC3T3-E1 subclone 4 pre-osteoblast, mouse (Mus musculus) -derived cell line was purchased from ATCC-CRL-2593. Minimum Essential Eagle’s Medium (α-MEM) (Corning, Corning, NY, USA), ascorbic acid (Avantor, Gliwice, Poland), β-glycerophosphate (Cayman Chemical, Ann Arbor, MI, USA) 100 units penicillin, 100 µg streptomycin, 250 ng amphotericin B per mL (ABAM, Sigma, St. Louis, MO, USA), fetal bovine serum (FBS, Biowest, Nuaillé, France), and trypsin/EDTA (Biowest) were also obtained [23]. We also used proliferation medium: α-MEM, 10% FBS, 1%vol. ABAM; differentiation medium: α-MEM, 10% FBS, 1%vol. ABAM, β-glycerophosphate 10 mM, ascorbic acid 50 µg/mL. Diclofenac (DF, J62609, Alfa Aesar, Kandel Germany, diclofenac sodium salt CAS number 15307-79-650) 50 mM stock in DMSO (dimethyl sulfoxide, sterile, catalogue number, DMS666, CAS Number 67-68-5 BioShop Canada Inc., Mainway Burlington, Ontario, Canada), final concentrations in differentiation culture media 50, 5, and 0.5 µM, methylprednisolone (MP, PHR1717-500MG, Merck, Darmstadt, Germany, C.A.S. Number 83-43-2) 50 mM stock in DMSO, final concentrations in differentiation culture media 50, 5 and 0.5 µM were also used.

2.2. Cell Viability and Caspase Activity

The 3-(4,5-dimethylthi-azol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-based Cell Growth Determination kit (Sigma) was used for cell viability analyses. Cells were incubated for 24, 48, 72, or 168 h with test substances in 24-well plates in the differentiation medium: α-MEM, 10% FBS, 1% vol. ABAM, β-glycerophosphate 10 mM, ascorbic acid 50 µg/mL. Finally, cells were incubated for 4 h in a differentiation medium with the addition of MTT (0.5 mg/mL). Subsequently, the cell culture medium was removed, and the solvent was added (1 mM hydrochloric acid in isopropanol anhydride (Avantor)). Following gentle mixing, analysis was performed using the Stat-Fax 2100 spectrophotometer (Awareness Technology Inc., Palm City, FL, USA) at a wavelength of 630 nm (background absorbance was measured at 405 nm).
Caspase activity was analyzed by a Caspase-Glo 3/7 assay (Promega Corporation, Madison, WI, USA). Following cell stimulation, Caspase-Glo 3/7 Reagent was added (culture medium: Caspase Glo 3/7 reagent, 4:1) to cells in a 96-well plate. After incubation for 1 h, luminescence was measured in the TD20/20 luminometer (Turner Designs Inc., Sunnyvale, CA, USA).

2.3. RNA Extraction and RT-PCR

Total RNA was extracted from the cultured MC3T3-E1 cells using TRItidy G, according to the manufacturer’s instructions (A4051,0100, Applichem, Darmstadt, Germany), and the High Pure Viral RNA Kit (1185882001, Roche, Mannheim, Germany) was used to purify the RNA. One µg of total RNA was used to synthesize cDNA in a 20 µL reaction containing 2.5–5 u/µL M-MLV Reverse Transcriptase Kit (28025-013, Thermo Fisher Scientific, Waltham, MA, USA), 1 u/µL RNaseOUT™ Recombinant Ribonuclease Inhibitor (10777-019, Thermo Fisher Scientific), 25 ng/µL oligo(dT)24, 10 ng/µL random hexamers, 2 mM dNTPs, and 10 mM DTT. The temperature program was: 65 °C for 5 min, ice chilling, 37 °C for 50 min, and 70 °C for 15 min.

2.4. Gene Expression

Gene expression was evaluated by qPCR, using the assays listed in Table 1. TaqMan Fast Advance Mix kit (4444963, Thermo Fisher Scientific) and LightCycler 96 or 480 (Roche Diagnostics, Basel, Switzerland) were used. The reaction conditions were the same for all assays: preheating 50 °C for 120 s, 95 °C for 120 s; amplification at 95 °C for 3 s, 60 °C for 30 s, repeated 45 times. The reaction mixture was: TaqMan Fast Advanced Master mix (2×) 5 µL, TaqMan Assay (20×) 0.5 µL, water 3.5 µL, and cDNA 1 µL. The crossing-point values were calculated automatically based on the second derivative algorithm, and the results were analyzed by the relative expression method, as in our previous work [24,25,26]. Hprt and B2m were used as reference genes.

2.5. Statistical Analysis

The data were analyzed using GraphPad InStat version 7.00 software (GraphPad Software, San Diego, CA, USA) and Statistica 13.0 software (TIBCO Software, Inc., Palo Alto, CA, USA). One-way ANOVA with Tukey’s post hoc test was used. The significance level was set at 5% (p < 0.05).
Real-time data were analyzed using Statistica and REST, the expression analysis software tool [25]. At first, the crossing-point values were calculated automatically based on the second derivative algorithm using the software LightCyclr 96 1.1.0.1320 (Roche Diagnostics International). The results were calculated to relative expression values using a standard curve specific for each gene. The relative values obtained were divided by the geometric mean of relative values of the reference genes Hprt and B2m. The geometric means of four independent biological repeats were used to calculate the results. The standard error of the mean was calculated using four biological repeat replications. The control expression levels at 24 h of incubation, without substances, were assumed to be one. Statistical analysis was performed on the logarithms of the relative expression values to obtain additive values, normality was confirmed using the Schapiro–Wilk’s test, and Leven’s test for homogeneity was performed, as well as the Tukey post-hoc test using Statistica 13.0 software (TIBCO Software, Inc.). Alternatively, the expression results were analyzed using the REST protocol [27]. These analyses results are available as Supplementary Data.

3. Results

3.1. Cell Viability

MC3T3-E1 cells were treated with DF and MP to determine whether these substances induced changes in cell viability. In Figure 1, we show that following 24 h of treatment with 50 µM MP, the MC3T3-E1 cell viability was decreased by 20%. The same treatment time with 50 µM DF did not reduce the viability of the MC3T3-E1 cells. The treatment of MC3T3-E1 cells with 0.5, 5, and 50 µM MP for 48 h diminished cell viability by almost 20%. The treatment of MC3T3-E1 cells with 0.5, 5, and 50 µM MP for 72 h diminished cell viability by 25–30%.
Treatment of MC3T3-E1 cells with 0.5 µM, 5 µM, and 50 µM MP for seven days diminished cell viability by more than 40%. The seven-day treatment time with 50 µM DF decreased the viability of MC3T3-E1 cells by almost 20%. The substances were administered once for each course experiment with the new differentiation medium. Over the seven days, the cells retreated after three days with the medium replacement procedure.

3.2. Caspase

MC3T3-E1 cells were treated with DF and MP to determine whether these drugs induced changes in the caspase-3 and -7 activities. We used the Caspase-Glo 3/7 assay to achieve the goal, which provides a proluminescent caspase-3/7 DVD-aminoluciferin substrate and a luciferase in reagent optimized for caspase-3/7 activities. Figure 2 shows that following 72 h of treatment with MP 0.5, 5, and 50 µM, the caspase-3 activity decreased in the MC3T3-E1 cells by 50%. The same treatment time with DF did not affect caspase 3 in the MC3T3-E1 cells. The treatment of MC3T3-E1 cells with MP 0.5, 5, and 50 µM for seven days diminished cell viability by 40%. Due to the diminished caspase-3 activity caused by MP, we determined that caspase-3 was not involved in the mechanism responsible for the decreased viability of MC3T3-E1 cells or their apoptosis. DF was not involved in the regulation of caspase-3 activations.

3.3. Gene Expression

Runx2 and Dlx5 homeobox transcription factors activate the expression of osterix (Osx, Sp7), which, in turn, activates the expression of the genes Satb2, encoding a transcription factor, and Col1a1, encoding collagen I [28]. Runx2, Dlx5 and Osx are key transcription factors associated with the differentiation of mesenchymal precursor cells into osteoblasts and osteocytes [29,30]. Figure 3 shows the relative expression of Osx (A and B,), Runx2 (C and D), Opn (E and F), and Col1a1 (G and H). Figure 4 shows Tgfb1 (A and B), Alp (C and D), Satb2 (E and F) and Dlx5 (G and H) values obtained by RT-PCR with TaqMan probes. Hprt and B2m were used as references for the mRNA level. DF did not significantly regulate gene expression. MP increased the expression of Runx2 after 72 h (Figure 3F). MP also increased the expression of Opn after seven days of treatment (Figure 3D). The expression of Col1a1 was diminished after seven days (Figure 3H).

4. Discussion

It has been noted that several non-selective NSAIDs and COX-2 selective inhibitors suppress bone remodeling. Bone repair has also been diminished in vivo as a side effect of pain treatment [9]. Depending on the study protocol, chronic administration of NSAIDs adversely affects the skeletal system and bone healing, and may also have a neutral impact [21]. Our previous study demonstrated that COX-2 inhibitor DF decreased bone mineral density in C57BL/6J mice [22]. Our present study shows that DF did not affect the gene expression of the osteogenic markers we tested. We revealed that DF exhibited decreased MC3T3-E1 viability after seven days, but the deregulation of the marker genes did not accompany this effect. MP effectively reduced cell viability, decreasing Col1a1 and increasing Runx2 expression.
MC3T3-E1 osteoblast progenitor cells originate from the C57BL/6 mouse strain. A suitable model to investigate NSAIDs’ effect on osteoblasts is isolated from mouse calvaria. MC3T3-E1 cells, by COX-2 induction, produce prostaglandins which trigger the prostaglandin extracellular receptor and the cAMP pathway [31]. Prostaglandin E could induce the proliferation of MC3T3-El and stimulated Egr-1, c-fos and c-jun expressions in MC3T3-E1 cells [32,33,34]. Prostaglandin is produced by MC3T3-E1 and stimulates its mineralization [35]. Since it has been revealed that MC3T3-E1 has secreted prostaglandin E and initiated the cAMP pathway, DF activity on MC3T3-E1 should reverse this effect.
DF is among the most effective NSAIDs, and it is a potent inhibitor of COX-2 and COX-1 [16]. Even though conclusive evidence regarding the teratogenicity of diclofenac in human embryos is lacking, animal studies have shown that administration of the drug at a high concentration in early gestation inhibits implantation and embryonic development of the bones [36]. It crosses the human placenta readily during the first trimester and should be considered as potentially teratogenic [37]. Previous in vivo and in vitro studies showed that DF decreased bone healing and decreased the viability of preosteoclasts [14]. DF is a type of NSAID that inhibits prostaglandin synthesis and affects bone cell osteogenic differentiation in cultured osteoblasts [9,14]. The exact mechanism of DF action in MC3T3-E1 cells, especially its effect on gene expression, remains unclear. Contrary to DF, methyloprednisolone, which easily enters into cells, is one of the GCs that strongly inhibits bone mineralization and differentiation.
As we expected, MP decreased cell viability. This observed decrease in cell viability cannot be explained by apoptosis because apoptotic marker caspase-3/7 was not increased. Eight marker genes were analyzed to reveal the effect of MP on pre-osteoblasts. In our study, after 72 h, Runx2 and Opn expression increased, and Col1a1 decreased in the presence of MP. However, in the earliest studies, in MC3T3-E1 cultures, it has been shown that GCs, either at physiological or pharmacological concentrations (DEX 1 µM for 72 hr), induce only modest alterations in the levels of Runx2 type I and type II [38]. We confirmed a strong MP effect diminishing osteoblast proliferation and decreasing gene expression. One possible explanation for these unexpected results regarding Runx2 and Opn gene expression in our study could be the inconsistencies between the gene expression profile of MC3T3-E1 subclone four and the primary calvarial osteoblasts [39]. The subclone information is not always available in publications [40]. These results partially confirm the earlier reported effect of MP on osteoblast cells and gene expression. Several authors have shown that DF has a weak impact on pre-osteoblast viability compared to MP.
It has been shown in previous studies that NSAIDs, including DF, decreased the MC3T3-E1 viability [14]. Our data are consistent with former observations, showing only a slight 20% decrease in MC3T3-E1 viability after seven days of DF treatment. The mechanisms by which NSAIDs exert their effect on pre-osteoblast cell growth are still under debate. In addition to the COX-2 dependent mechanism, DF could exert an antiproliferative effect using several alternative pathways [16]. In rat calvaria osteoprogenitor cells, therapeutic doses of DF promoted cell death by arresting their cell cycle in phase G0/G1, which may suppress tissue formation and bone remodeling [9].
To provide more insight into the mechanism of the action of DF in the pre-osteoblastic MC3T3-E1 cells, we investigated osteogenic marker gene expression. We did not observe significant variation in gene expression in the presence of DF. Hadjicharalambous et al. applied 10−5 and 10−6 DF in MC3T3-E1 cells for 5, 10, and 15 days, but the authors did not investigate several prominent osteogenic marker genes in the treated cells [14]. Hadjicharalambous et al., using MC3T3-E1 incubated with several COX-2 selective NSAIDs, revealed that none of the NSAIDs affected the expression of either the Runx2 or Bsp genes. In human primary osteoblast cell cultures, RUNX-2, COL1A1, and OSX expression were reduced by treatment with all NSAIDs and DF [20].
We checked DF in pre-osteoblast cells to reveal how DF decreased bone mineral density in the C57BL/6J mice. Although in our previous study, the mouse cells were treated with DF for 28 days, the short-term gene expression assay in the MC3T3-E1 cells ought to reveal at least minor changes in gene expression. Since the gene expression in MC3T3-E1 was not significantly modified by DF, the explanation for the decrease in bone mineral density in mice is likely due to other mechanisms. The effect might be due to DF’s impact on osteoclasts or mature osteoblasts, or possibly the systemic effect of DF on steroid hormone secretion in the gonads.
The limitation of the study is that there was not an application of another cell line as an osteoclast to explain the effects of DF on bone mineral density. Since the mice in our former experiment received DF daily by injection, the cell culture may also require daily retreatment with DF and MP. The mechanism of MP action on Col1a1, Runx2, and Opn gene expression and their interplay should be further investigated. The MP action on cell proliferation, independent of prostaglandin, should be exploited. Future work in deciphering NSAIDs and GCs should answer the question regarding the mechanism of MP action involving or not involving prostaglandin synthesis. The effect of DF on MC3T3-E1 should be verified concerning the COX-1 and COX-2 expression level and prostaglandin production.

5. Conclusions

We concluded that DF exhibits fewer harmful effects on the osteoblasts than does MP. For the first time, we showed that the previoulsy observed decrease in MC3T3-E1 proliferation is not strongly associated with gene expression in pre-osteoblasts.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/genes14010184/s1, REST program results in excel files [27] are shown in four Excel Tables S1–S4. They contain gene expression results after 24 h, 48 h, 72 h, and 168 h with DF and MP. Samples are compared in 6 conditions: Condition I—DF 0.5 µM, Condition II—DF 5 µM, Condition III DF 50 µM, Condition IV—MP 0.5 µM, Condition V—MP 5 µM, Condition VI—MP 50 µM. Table S1: Gene expression analysis after 24 h with DF and MP. Table S2: Gene expression analysis after 48 h with DF and MP. Table S3: Gene expression analysis after 72 h with DF and MP. Table S4: Gene expression analysis after 168 h with DF and MP.

Author Contributions

T.P.L. made substantial contributions to the research design, as well as the acquisition, analysis, and interpretation of data; E.I.-S. made significant contributions to the acquisition, analysis, and interpretation of data; P.P.J. and J.H. drafted the paper and edited the final version; M.G. substantially contributed to the research design, as well as the acquisition, analysis and interpretation of data, and the drafting and critical revision of the paper. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Polish National Science Center (NCN), a Polish governmental agency, project number: 2016/21/B/NZ7/02748 (OPUS 11 competition). This paper was not supported by any commercial resources.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data is contained within the article or Supplementary Material.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Gómez-Acebo, I.; Dierssen-Sotos, T.; de Pedro, M.; Pérez-Gómez, B.; Castaño-Vinyals, G.; Fernández-Villa, T.; Palazuelos-Calderón, C.; Amiano, P.; Etxeberria, J.; Benavente, Y.; et al. Epidemiology of Non-Steroidal Anti-Inflammatory Drugs Consumption in Spain. The MCC-Spain Study. BMC Public Health 2018, 18, 1134. [Google Scholar] [CrossRef]
  2. Felson, D.T.; Neogi, T. Emerging Treatment Models in Rheumatology: Challenges for Osteoarthritis Trials. Arthritis Rheumatol. 2018, 70, 1175–1181. [Google Scholar] [CrossRef] [Green Version]
  3. Hardy, R.S.; Zhou, H.; Seibel, M.J.; Cooper, M.S. Glucocorticoids and Bone: Consequences of Endogenous and Exogenous Excess and Replacement Therapy. 2018. Endocr. Rev. 2018, 39, 519–548. [Google Scholar] [CrossRef] [Green Version]
  4. Takahata, M.; Maher, J.R.; Juneja, S.C.; Inzana, J.; Xing, L.; Schwarz, E.M.; Berger, A.J.; Awad, H.A. Mechanisms of Bone Fragility in a Mouse Model of Glucocorticoid-Treated Rheumatoid Arthritis: Implications for Insufficiency Fracture Risk. Arthritis Rheum. 2012, 64, 3649–3659. [Google Scholar] [CrossRef] [Green Version]
  5. Ersek, A.; Santo, A.I.; Vattakuzhi, Y.; George, S.; Clark, A.R.; Horwood, N.J. Strain Dependent Differences in Glucocorticoid-Induced Bone Loss between C57BL/6J and CD-1 Mice. Sci. Rep. 2016, 6, 36513. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Glowacki, M.; Ignys-O’Byrne, A.; Ignys, I.; Mankowski, P.; Melzer, P. Evaluation of Volume and Solitary Bone Cyst Remodeling Using Conventional Radiological Examination. Skeletal Radiol. 2010, 39, 251–259. [Google Scholar] [CrossRef] [PubMed]
  7. Glowacki, M.; Ignys-O’Byrne, A.; Ignys, I.; Wroblewska, K. Limb Shortening in the Course of Solitary Bone Cyst Treatment—A Comparative Study. Skeletal Radiol. 2011, 40, 173–179. [Google Scholar] [CrossRef]
  8. Czarny-Ratajczak, M.; Bieganski, T.; Rogala, P.; Glowacki, M.; Trzeciak, T.; Kozlowski, K. New Intermediate Phenotype between MED and DD Caused by Compound Heterozygous Mutations in the DTDST Gene. Am. J. Med. Genet. A 2010, 152A, 3036–3042. [Google Scholar] [CrossRef]
  9. Ho, M.L.; Chang, J.K.; Chuang, L.Y.; Hsu, H.K.; Wang, G.J. Effects of Nonsteroidal Anti-Inflammatory Drugs and Prostaglandins on Osteoblastic Functions. Biochem. Pharm. 1999, 58, 983–990. [Google Scholar] [CrossRef] [PubMed]
  10. Manzano-Moreno, F.J.; Costela-Ruiz, V.J.; Melguizo-Rodríguez, L.; Illescas-Montes, R.; García-Martínez, O.; Ruiz, C.; Ramos-Torrecillas, J. Inhibition of VEGF Gene Expression in Osteoblast Cells by Different NSAIDs. Arch. Oral. Biol. 2018, 92, 75–78. [Google Scholar] [CrossRef]
  11. García-Martínez, O.; de Luna-Bertos, E.; Ramos-Torrecillas, J.; Manzano-Moreno, F.J.; Ruiz, C. Repercussions of NSAIDS Drugs on Bone Tissue: The Osteoblast. Life Sci. 2015, 123, 72–77. [Google Scholar] [CrossRef] [PubMed]
  12. Datta, H.K.; Ng, W.F.; Walker, J.A.; Tuck, S.P.; Varanasi, S.S. The Cell Biology of Bone Metabolism. J. Clin. Pathol. 2008, 61, 577–587. [Google Scholar] [CrossRef]
  13. Kaspar, D.; Hedrich, C.M.; Schmidt, C.; Liedert, A.; Claes, L.E.; Ignatius, A.A. Diclofenac Inhibits Proliferation and Matrix Formation of Osteoblast Cells. Unfallchirurg 2005, 108, 18–24. [Google Scholar] [CrossRef] [PubMed]
  14. Hadjicharalambous, C.; Alpantaki, K.; Chatzinikolaidou, M. Effects of NSAIDs on Pre-Osteoblast Viability and Osteogenic Differentiation. Exp. Ther. Med. 2021, 22, 740. [Google Scholar] [CrossRef] [PubMed]
  15. Chang, J.-K.; Li, C.-J.; Wu, S.-C.; Yeh, C.-H.; Chen, C.-H.; Fu, Y.-C.; Wang, G.-J.; Ho, M.-L. Effects of Anti-Inflammatory Drugs on Proliferation, Cytotoxicity and Osteogenesis in Bone Marrow Mesenchymal Stem Cells. Biochem. Pharm. 2007, 74, 1371–1382. [Google Scholar] [CrossRef] [PubMed]
  16. Gan, T.J. Diclofenac: An Update on Its Mechanism of Action and Safety Profile. Curr. Med. Res. Opin. 2010, 26, 1715–1731. [Google Scholar] [CrossRef]
  17. Chang, J.-K.; Li, C.-J.; Liao, H.-J.; Wang, C.-K.; Wang, G.-J.; Ho, M.-L. Anti-Inflammatory Drugs Suppress Proliferation and Induce Apoptosis through Altering Expressions of Cell Cycle Regulators and pro-Apoptotic Factors in Cultured Human Osteoblasts. Toxicology 2009, 258, 148–156. [Google Scholar] [CrossRef]
  18. Díaz-Rodríguez, L.; García-Martínez, O.; Morales, M.A.-; Rodríguez-Pérez, L.; Rubio-Ruiz, B.; Ruiz, C. Effects of Indomethacin, Nimesulide, and Diclofenac on Human MG-63 Osteosarcoma Cell Line. Biol. Res. Nurs. 2012, 14, 98–107. [Google Scholar] [CrossRef]
  19. Karakawa, A.; Fukawa, Y.; Okazaki, M.; Takahashi, K.; Sano, T.; Amano, H.; Yamamoto, M.; Yamada, S. Diclofenac Sodium Inhibits NFkappaB Transcription in Osteoclasts. J. Dent. Res. 2009, 88, 1042–1047. [Google Scholar] [CrossRef] [PubMed]
  20. Melguizo-Rodriguez, L.; Costela-Ruiz, V.J.; Manzano-Moreno, F.J.; Illescas-Montes, R.; Ramos-Torrecillas, J.; Garcia-Martinez, O.; Ruiz, C. Repercussion of Nonsteroidal Anti-Inflammatory Drugs on the Gene Expression of Human Osteoblasts. PeerJ 2018, 6, e5415. [Google Scholar] [CrossRef]
  21. Pountos, I.; Georgouli, T.; Calori, G.M.; Giannoudis, P.V. Do Nonsteroidal Anti-Inflammatory Drugs Affect Bone Healing? A Critical Analysis. Sci. World J. 2012, 2012, 606404. [Google Scholar] [CrossRef] [Green Version]
  22. Lehmann, T.P.; Wojtków, M.; Pruszyńska-Oszmałek, E.; Kołodziejski, P.; Pezowicz, C.; Trzaskowska, A.; Mielcarek, S.; Szybowicz, M.; Nowicka, A.B.; Nowicki, M.; et al. Trabecular Bone Remodelling in the Femur of C57BL/6J Mice Treated with Diclofenac in Combination with Treadmill Exercise. Acta Bioeng. Biomech. 2021, 23, 3–11. [Google Scholar] [CrossRef]
  23. Lehmann, T.P.; Juzwa, W.; Filipiak, K.; Sujka-Kordowska, P.; Zabel, M.; Gowacki, J.; Gowacki, M.; Jagodziski, P.P. Quantification of the Asymmetric Migration of the Lipophilic Dyes, DiO and DiD, in Homotypic Co-Cultures of Chondrosarcoma SW-1353 Cells. Mol. Med. Rep. 2016, 14, 4529–4536. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Lehmann, T.P.; Filipiak, K.; Juzwa, W.; Sujka-Kordowska, P.; Jagodziński, P.P.; Zabel, M.; Głowacki, J.; Misterska, E.; Walczak, M.; Głowacki, M. Co-Culture of Human Nucleus Pulposus Cells with Multipotent Mesenchymal Stromal Cells from Human Bone Marrow Reveals Formation of Tunnelling Nanotubes. Mol. Med. Rep. 2014, 9, 574–582. [Google Scholar] [CrossRef] [Green Version]
  25. Lehmann, T.P.; Głowacki, M.; Misterska, E.; Walczak, M.; Jagodziński, P.P.; Głowacki, J. Anti-Tuberculosis Drugs Decrease Viability and Stimulate the Expression of Chondrocyte Marker Genes in Human Nucleus Pulposus Cells. Mol. Med. Rep. 2014, 9, 316–322. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Lehmann, T.P.; Jakub, G.; Harasymczuk, J.; Jagodziński, P.P. Transforming Growth Factor β Mediates Communication of Co-Cultured Human Nucleus Pulposus Cells and Mesenchymal Stem Cells. J. Orthop. Res. 2018, 36, 3023–3032. [Google Scholar] [CrossRef] [Green Version]
  27. Pfaffl, M.W.; Horgan, G.W.; Dempfle, L. Relative Expression Software Tool (REST) for Group-Wise Comparison and Statistical Analysis of Relative Expression Results in Real-Time PCR. Nucleic. Acids. Res. 2002, 30, e36. [Google Scholar] [CrossRef] [PubMed]
  28. Ortuno, M.J.; Susperregui, A.R.; Artigas, N.; Rosa, J.L.; Ventura, F. Osterix Induces Col1a1 Gene Expression through Binding to Sp1 Sites in the Bone Enhancer and Proximal Promoter Regions. Bone 2013, 52, 548–556. [Google Scholar] [CrossRef]
  29. Farshdousti Hagh, M.; Noruzinia, M.; Mortazavi, Y.; Soleimani, M.; Kaviani, S.; Abroun, S.; Dehghani Fard, A.; Mahmoodinia, M. Different Methylation Patterns of RUNX2, OSX, DLX5 and BSP in Osteoblastic Differentiation of Mesenchymal Stem Cells. Cell J. 2015, 17, 71–82. [Google Scholar] [CrossRef]
  30. Liu, Q.; Li, M.; Wang, S.; Xiao, Z.; Xiong, Y.; Wang, G. Recent Advances of Osterix Transcription Factor in Osteoblast Differentiation and Bone Formation. Front. Cell Dev. Biol. 2020, 8, 601224. [Google Scholar] [CrossRef]
  31. Watanabe-Tomita, Y.; Suzuki, A.; Oiso, Y.; Kozawa, O. Prostaglandin E1 Stimulates Interleukin-6 Secretion via Protein Kinase A in Osteoblast-like Cells. Cell Signal. 1997, 9, 105–108. [Google Scholar] [CrossRef] [PubMed]
  32. Hakeda, Y.; Harada, S.; Matsumoto, T.; Tezuka, K.; Higashino, K.; Kodama, H.; Hashimoto-Goto, T.; Ogata, E.; Kumegawa, M. Prostaglandin F2 Alpha Stimulates Proliferation of Clonal Osteoblastic MC3T3-E1 Cells by up-Regulation of Insulin-like Growth Factor I Receptors. J. Biol. Chem. 1991, 266, 21044–21050. [Google Scholar] [CrossRef]
  33. Fang, M.A.; Noguchi, G.M.; McDougall, S. Prostaglandin E2 Induces Egr-1 MRNA in MC3T3-E1 Osteoblastic Cells by a Protein Kinase C-Dependent Pathway. Prostaglandins Leukot. Essent. Fat. Acids 1996, 54, 109–114. [Google Scholar] [CrossRef] [PubMed]
  34. Suda, M.; Tanaka, K.; Sakuma, Y.; Yasoda, A.; Ozasa, A.; Fukata, J.; Tanaka, I.; Narumiya, S.; Nakao, K. Prostaglandin E(2) (PGE(2)) Induces the c-Fos and c-Jun Expressions via the EP(1) Subtype of PGE Receptor in Mouse Osteoblastic MC3T3-E1 Cells. Calcif. Tissue Int. 2000, 66, 217–223. [Google Scholar] [CrossRef]
  35. Suzuki, H.; Ohshima, N.; Tatei, K.; Taniguchi, T.; Sato, S.; Izumi, T. The Role of Autonomously Secreted PGE2 and Its Autocrine/Paracrine Effect on Bone Matrix Mineralization at the Different Stages of Differentiating MC3T3-E1 Cells. Biochem. Biophys. Res. Commun. 2020, 524, 929–935. [Google Scholar] [CrossRef] [PubMed]
  36. El-Sayed, M.G.A.; El-Komy, A.A.A.; Dalia, D.I.A.E. Evaluation of Teratogenic Potentials of Diclofenac in Pregnant Female Rats. Benha. Vet. Med. J. 2014, 26, 54–66. [Google Scholar]
  37. Siu, S.S.; Yeung, J.H.; Lau, T.K. A Study on Placental Transfer of Diclofenac in First Trimester of Human Pregnancy. Hum. Reprod. 2000, 15, 2423–2425. [Google Scholar] [CrossRef] [Green Version]
  38. Luppen, C.A.; Smith, E.; Spevak, L.; Boskey, A.L.; Frenkel, B. Bone Morphogenetic Protein-2 Restores Mineralization in Glucocorticoid-Inhibited MC3T3-E1 Osteoblast Cultures. J. Bone. Miner. Res. 2003, 18, 1186–1197. [Google Scholar] [CrossRef]
  39. Hwang, P.W.; Horton, J.A. Variable Osteogenic Performance of MC3T3-E1 Subclones Impacts Their Utility as Models of Osteoblast Biology. Sci. Rep. 2019, 9, 8299. [Google Scholar] [CrossRef] [Green Version]
  40. Xu, D.; Gao, Y.; Hu, N.; Wu, L.; Chen, Q. MiR-365 Ameliorates Dexamethasone-Induced Suppression of Osteogenesis in MC3T3-E1 Cells by Targeting HDAC4. Int. J. Mol. Sci. 2017, 18, 977. [Google Scholar] [CrossRef]
Genes 14 00184 g001 550
Figure 1. Comparison of the effects of diclofenac (DF) and methylprednisolone (MP) on the viability of MC3T3-E1 pre-osteoblast cells. The MC3T3-E1 cells were treated for 24 h, 48 h, 72 h, and 168 h (A–D) with three concentrations of DF (open bars) and MP (black bars): 0.5 µM, 5 µM, and 50 µM. The viability of the cells, determined by the 3-(4,5-dimethylthi- azol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, was expressed as the mean ± SD from four experiments and was compared to the untreated control. It was assumed that the viability of the control cells equals 100%. The significance was evaluated using one-way ANOVA with Tukey’s post hoc test. The significance level was set at 5% (p < 0.05); significant at: * p < 0.05, ** p < 0.01, and *** p < 0.001.
Figure 1. Comparison of the effects of diclofenac (DF) and methylprednisolone (MP) on the viability of MC3T3-E1 pre-osteoblast cells. The MC3T3-E1 cells were treated for 24 h, 48 h, 72 h, and 168 h (A–D) with three concentrations of DF (open bars) and MP (black bars): 0.5 µM, 5 µM, and 50 µM. The viability of the cells, determined by the 3-(4,5-dimethylthi- azol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, was expressed as the mean ± SD from four experiments and was compared to the untreated control. It was assumed that the viability of the control cells equals 100%. The significance was evaluated using one-way ANOVA with Tukey’s post hoc test. The significance level was set at 5% (p < 0.05); significant at: * p < 0.05, ** p < 0.01, and *** p < 0.001.
Genes 14 00184 g001
Genes 14 00184 g002 550
Figure 2. Comparison of the impact of MP and DF on the caspase-3 and caspase-7 activities in MC3T3-E1 pre-osteoblast cells. After 72 h and seven days of treatment with DF (open bars) and MP (black bars), the MC3T3-E1 cells were lysed. The activity of caspase-3 and caspase-7 were determined in triplicate using the Caspase-Glo 3/7 assay (Promega Corporation, Madison, WI, USA), as described in the Materials and Methods section. Results were the mean ± SD of four separate experiments, the untreated control assuming that the caspase activity of the control cells equals 1. The significance was evaluated using one-way ANOVA with Tukey’s post hoc test. The significance level was set at 5% (* p < 0.05); significant at: ** p < 0.01, and *** p < 0.001.
Figure 2. Comparison of the impact of MP and DF on the caspase-3 and caspase-7 activities in MC3T3-E1 pre-osteoblast cells. After 72 h and seven days of treatment with DF (open bars) and MP (black bars), the MC3T3-E1 cells were lysed. The activity of caspase-3 and caspase-7 were determined in triplicate using the Caspase-Glo 3/7 assay (Promega Corporation, Madison, WI, USA), as described in the Materials and Methods section. Results were the mean ± SD of four separate experiments, the untreated control assuming that the caspase activity of the control cells equals 1. The significance was evaluated using one-way ANOVA with Tukey’s post hoc test. The significance level was set at 5% (* p < 0.05); significant at: ** p < 0.01, and *** p < 0.001.
Genes 14 00184 g002
Genes 14 00184 g003 550
Figure 3. Gene expression in MC3T3-E1 in the presence of DF and MP. Osx, Runx2, Opn, and Col1a1 mRNA levels in MC3T3-E1 cells treated with DF (A,C,E,G) 0.5 µM, 5 µM, 50 µM (increasing grey scale, respectively) for 24 h, 48 h, 72 h, and 168 h. MC3T3-E1 cells were treated with MP (B,D,F,H) 0.5, 5, 50 µM (increasing grey scale, respectively) for 24 h, 48 h, 72 h, and 168 h. Untreated control equals 1 (open bars). Results are presented as geometric means of relative expression. Hprt and B2m were used as reference genes. The significance was evaluated using one-way ANOVA with Tukey’s post hoc test. The significance level was set at 5% (p < 0.05). Error bars represent ± SEM. * p < 0.05.
Figure 3. Gene expression in MC3T3-E1 in the presence of DF and MP. Osx, Runx2, Opn, and Col1a1 mRNA levels in MC3T3-E1 cells treated with DF (A,C,E,G) 0.5 µM, 5 µM, 50 µM (increasing grey scale, respectively) for 24 h, 48 h, 72 h, and 168 h. MC3T3-E1 cells were treated with MP (B,D,F,H) 0.5, 5, 50 µM (increasing grey scale, respectively) for 24 h, 48 h, 72 h, and 168 h. Untreated control equals 1 (open bars). Results are presented as geometric means of relative expression. Hprt and B2m were used as reference genes. The significance was evaluated using one-way ANOVA with Tukey’s post hoc test. The significance level was set at 5% (p < 0.05). Error bars represent ± SEM. * p < 0.05.
Genes 14 00184 g003
Genes 14 00184 g004 550
Figure 4. Gene expression in MC3T3-E1 in the presence of DF and MP. Tgfb1, Alp, Satb2, and Dlx5 mRNA levels in MC3T3-E1 cells treated with DF (A,C,E,G) 0.5 µM, 5 µM, 50 µM (increasing grey scale, respectively) for 24 h, 48 h, 72 h, and 168 h. MC3T3-E1 cells were treated with MP (B,D,F,H) 0.5 µM, 5 µM, 50 µM (increasing grey scale, respectively) for 24 h, 48 h, 72 h, and 168 h. Untreated control equals 1 (open bars). Results are presented as geometric means of relative expression. Hprt and B2m were used as reference genes. The significance was evaluated using one-way ANOVA with Tukey’s post hoc test. The significance level was set at 5% (p < 0.05). Error bars represent ± SEM.
Figure 4. Gene expression in MC3T3-E1 in the presence of DF and MP. Tgfb1, Alp, Satb2, and Dlx5 mRNA levels in MC3T3-E1 cells treated with DF (A,C,E,G) 0.5 µM, 5 µM, 50 µM (increasing grey scale, respectively) for 24 h, 48 h, 72 h, and 168 h. MC3T3-E1 cells were treated with MP (B,D,F,H) 0.5 µM, 5 µM, 50 µM (increasing grey scale, respectively) for 24 h, 48 h, 72 h, and 168 h. Untreated control equals 1 (open bars). Results are presented as geometric means of relative expression. Hprt and B2m were used as reference genes. The significance was evaluated using one-way ANOVA with Tukey’s post hoc test. The significance level was set at 5% (p < 0.05). Error bars represent ± SEM.
Genes 14 00184 g004
Table
Table 1. Gene and assay ID numbers.
Table 1. Gene and assay ID numbers.
GeneAssay Catalogue NumberSequence ID
Osx4351372Mm04933803_m1
Runx24331182Mm00501584_m1
Opn/Spp14331182Mm00436767_m1
Col1a14331182Mm00801666_g1
Tgfb14331182Mm01178820_m1
Alp4331182Mm00475834_m1
Satb24331182Mm00507331_m1
Dlx54331182Mm00438430_m1
Hprt4331182Mm03024075_m1
B2m4331182Mm00437764_m1
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Lehmann, T.P.; Iwańczyk-Skalska, E.; Harasymczuk, J.; Jagodziński, P.P.; Głowacki, M. Gene Expression in MC3T3-E1 Cells Treated with Diclofenac and Methylprednisolone. Genes 2023, 14, 184. https://doi.org/10.3390/genes14010184

AMA Style

Lehmann TP, Iwańczyk-Skalska E, Harasymczuk J, Jagodziński PP, Głowacki M. Gene Expression in MC3T3-E1 Cells Treated with Diclofenac and Methylprednisolone. Genes. 2023; 14(1):184. https://doi.org/10.3390/genes14010184

Chicago/Turabian Style

Lehmann, Tomasz P., Ewa Iwańczyk-Skalska, Jerzy Harasymczuk, Paweł P. Jagodziński, and Maciej Głowacki. 2023. "Gene Expression in MC3T3-E1 Cells Treated with Diclofenac and Methylprednisolone" Genes 14, no. 1: 184. https://doi.org/10.3390/genes14010184

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop